Clinical Trials · NCT04921124

Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes

CompletedPhase 3Teriparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Norfolk and Norwich University Hospitals NHS Foundation Trust
Enrollment
30
Start date
May 2021
Locations
1 site, United Kingdom
Primary endpoint
Concentration over time assessed by the area under the curve (AUC) of teriparatide (PTH (1-34)).
View Teriparatide compound reference